transcellular metabolism
Recently Published Documents


TOTAL DOCUMENTS

26
(FIVE YEARS 0)

H-INDEX

11
(FIVE YEARS 0)

2015 ◽  
Vol 114 (09) ◽  
pp. 469-477 ◽  
Author(s):  
Karsten Schrör ◽  
Thomas Hohlfeld

SummaryVascular injury in acute coronary syndromes (ACS) involves a complex cross-talk between inflammatory mediators, platelets and thrombosis, where the interaction between platelets and coagulation factors (e. g. thrombin) is a central link between thrombosis and inflammation. In ACS, aspirin at antiplatelet doses exhibits anti-inflammatory effects as seen from the decrease in inflammation markers such as CRP, M-CSF, MCP-1 and others. These actions probably occur subsequent to inhibition of platelet COX-1-dependent thromboxane formation and its action as a multipotent autocrine and paracrine agent. This likely involves inhibition of thrombin formation as well as inhibition of secondary pro-inflammatory mediators, such as sphingosine-1-phosphate. Experimental and limited clinical data additionally suggest antiinflammatory effects of aspirin independent of its antiplatelet action. For example, aspirin at antiplatelet doses might acetylate COX-2 in vascular cells, directing the activity of the enzyme into a 15-lipoxygenase which by transcellular metabolism results in the formation of 15-epi-lipoxin (‘aspirin-triggered lipoxin’), an antiinflammatory mediator. Furthermore, aspirin stimulates eNOS via lysine-acetylation, eventually resulting in induction of heme oxygenase (HO-1), which improves the antioxidative potential of vascular cells. All of these effects have been seen at antiplatelet doses of 100–300 mg/day, equivalent to peak plasma levels of 10–30 μM. Many more potentially antiinflammatory mechanisms of aspirin have been described, mostly salicy-late-related, at low to medium millimolar concentrations and, therefore, are of minor clinical interest. Altogether, there is a wealth of data supporting antiiflammatory effects of aspirin in ACS, but studies generating direct evidence for antiinflammatory effects in ACS remain to be done.


2009 ◽  
Vol 29 (7) ◽  
pp. 1131-1137 ◽  
Author(s):  
M. Dolores Salvado ◽  
Arántzazu Alfranca ◽  
Amelia Escolano ◽  
Jesper Z. Haeggström ◽  
Juan Miguel Redondo

2006 ◽  
Vol 6 (1) ◽  
pp. 37-47 ◽  
Author(s):  
Lesley C. Wright ◽  
Rosemary M. Santangelo ◽  
Ranjini Ganendren ◽  
Jackie Payne ◽  
Julianne T. Djordjevic ◽  
...  

ABSTRACT Cryptococci survive and replicate within macrophages and can use exogenous arachidonic acid for the production of eicosanoids. Phospholipase B1 (PLB1) has a putative, but uninvestigated, role in these processes. We have shown that uptake and esterification of radiolabeled arachidonic, palmitic, and oleic acids by the Cryptococcus neoformans var. grubii H99 wild-type strain and its PLB1 deletion mutant strain (the Δplb1 strain) are independent of PLB1, except under hyperosmolar stress. Similarly, PLB1 was required for metabolism of 1-palmitoyl lysophosphatidylcholine (LysoPC), which is toxic to eukaryotic cell membranes, under hyperosmolar conditions. During both logarithmic and stationary phases of growth, the physiologically relevant phospholipids, dipalmitoyl phosphatidylcholine (DPPC) and dioleoyl phosphatidylcholine, were taken up and metabolized via PLB1. Exogenous DPPC did not enhance growth in the presence of glucose as a carbon source but could support it for at least 24 h in glucose-free medium. Detoxification of LysoPC by reacylation occurred in both the H99 wild-type and the Δplb1 strains in the presence of glucose, but PLB1 was required when LysoPC was the sole carbon source. This indicates that both energy-independent (via PLB1) and energy-dependent transacylation pathways are active in cryptococci. Phospholipase A1 activity was identified by PLB1-independent degradation of 1-palmitoyl-2-arachidonoyl phosphatidylcholine, but the arachidonoyl LysoPC formed was not detoxified by reacylation. Using the human macrophage-like cell line THP-1, we demonstrated the PLB1-dependent incorporation of macrophage-derived arachidonic acid into cryptococcal lipids during cryptococcus-phagocyte interaction. This pool of arachidonate can be sequestered for eicosanoid production by the fungus and/or suppression of host phagocytic activity, thus diminishing the immune response.


2001 ◽  
Vol 107 (5) ◽  
pp. 824-831 ◽  
Author(s):  
Isabelle Vachier ◽  
Claude Chavis ◽  
Maria Majori ◽  
Martine Farce ◽  
Jean Bousquet ◽  
...  

1994 ◽  
Vol 30 (4) ◽  
pp. 353
Author(s):  
Angelo Sala ◽  
Giuseppe Rossoni ◽  
Ferruccio Berti ◽  
Jacques Maclouf ◽  
Giancarlo Folco

Sign in / Sign up

Export Citation Format

Share Document